Maria Vargas, MD
Endocrinology, Diabetes & Metabolism · Tulsa, OKNPI 1821173568
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 362 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,452 and has fallen 52.2% since, to $695 in 2025.
Across 362 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- AstraZeneca$801
- Dexcom, Inc.$796
- Novo Nordisk$697
- Boehringer Ingelheim$632
- Lilly USA, LLC$470
- plus $2K from 33 others
What the payments were for
- Food & beverage$6,65697%
- Education$2023%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 66 | $1,007 |
| AstraZeneca(2 entities) | 32 | $801 |
| Dexcom, Inc. | 63 | $796 |
| Novo Nordisk | 44 | $697 |
| Boehringer Ingelheim | 30 | $632 |
| Lilly USA, LLC | 22 | $470 |
| Johnson & Johnson | 5 | $349 |
| Bayer | 11 | $200 |
| Insulet Corporation | 13 | $170 |
| Eisai Inc. | 2 | $147 |
| Ultragenyx Pharmaceutical Inc. | 5 | $125 |
| Amgen | 8 | $112 |
| Valeritas, Inc. | 2 | $108 |
| Chiesi USA, Inc. | 5 | $103 |
| Radius Health, Inc. | 1 | $100 |
| Corcept Therapeutics | 3 | $90 |
| Mannkind Corporation | 3 | $82 |
| Currax Pharmaceuticals LLC | 4 | $70 |
| AbbVie | 4 | $70 |
| Amarin Pharma, Inc. | 4 | $64 |
| Sanofi-aventis U.S. LLC | 3 | $59 |
| Xeris Pharmaceuticals, Inc. | 3 | $54 |
| Amryt Pharma Holdings Ltd | 3 | $53 |
| Medtronic(2 entities) | 3 | $53 |
| Endo Pharmaceuticals Inc. | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Madrigal Pharmaceuticals | 2 | $42 |
| IBSA Pharma Inc. | 3 | $40 |
| Ascendis Pharma Endocrinology Inc | 2 | $39 |
| Lifescan, Inc. | 2 | $35 |
| Senseonics, Incorporated | 1 | $33 |
| Astellas Pharma US Inc | 1 | $28 |
| BETA Bionics, Inc. | 1 | $25 |
| Stryker | 1 | $25 |
| Corium, LLC | 1 | $24 |
| Tandem Diabetes Care, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Antares Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,858 in reported general payments places this provider in the 65th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 120 | $160,577 |
| TrulicityDulaglutide | 99 | $100,774 |
| MounjaroTirzepatide | 59 | $79,966 |
| Tresiba Flextouch U-200Insulin Degludec | 61 | $58,940 |
| JardianceEmpagliflozin | 68 | $56,259 |
| Tresiba Flextouch U-100Insulin Degludec | 50 | $39,901 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $26,741 |
| FarxigaDapagliflozin Propanediol | 25 | $26,105 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 15 | $25,793 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 21 | $21,590 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $21,554 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 32 | $20,349 |
| Novolog FlexpenInsulin Aspart | 78 | $19,130 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 23 | $15,811 |
| Humalog Kwikpen U-200Insulin Lispro | 20 | $15,459 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $470 | $185,166174 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $697 | $174,183146 claims |
| Boehringer IngelheimJardiance, Tradjenta | $632 | $70,30384 claims |
| AstraZenecaFarxiga | $801 | $26,10525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Tulsa
- Cristin BrunsTulsa$159K
- Donald AspensonTulsa$153K
- Hanna FoggTulsa$25K
- Mario Bustos RodriguezTulsa$19K
- Elie AbedTulsa$10K
- Vishnu Priya PulipatiTulsa$8K
- Christian HansonTulsa$4K
- Miguel Jara PalaciosTulsa$4K
- Deepa PhilipTulsa$4K
- Alekya PolojuTulsa$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.